Results of multivariate models of time to GVHD, time to treatment-related mortality, and overall survival using threshold day 7 TNFR1 ratio
| Variable . | Category . | GVHD . | TRM . | OS . | |||
|---|---|---|---|---|---|---|---|
| HR . | P . | HR . | P . | HR . | P . | ||
| Day 7 TNFR1 ratio | ≤ 2.5 | Ref | — | Ref | — | Ref | — |
| > 2.5 | 2.44 | <.001 | 2.40 | <.001 | 1.39 | .03 | |
| Donor type | MRD | Ref | — | Ref | — | Ref | — |
| MUD | 1.87 | <.001 | 3.25 | <.001 | 1.49 | .006 | |
| Match | Yes | Ref | — | Ref | — | Ref | — |
| No | 1.93 | .01 | 1.09 | .79 | 1.25 | .28 | |
| Recipient age* | 1.05 | .35 | 1.28 | .002 | 1.10 | .03 | |
| Donor → recipient | Male → male | Ref | — | Ref | — | Ref | — |
| Female → male | 1.29 | .19 | 1.26 | .39 | 1.02 | .90 | |
| Sex | Male → female | .63 | .04 | .69 | .19 | .88 | .46 |
| Female → female | .80 | .54 | .75 | .57 | 1.01 | .98 | |
| Diagnosis and disease status | Nonmalignant | Ref | — | Ref | — | Ref | — |
| Standard risk | 1.65 | .36 | .96 | .96 | 4.26 | .05 | |
| Advanced risk | 1.74 | .31 | 1.31 | .70 | 7.67 | .005 | |
| Preparative regimen | Non-TBI | Ref | — | Ref | — | Ref | — |
| TBI | 1.14 | .63 | .61 | .20 | 1.18 | .45 | |
| Variable . | Category . | GVHD . | TRM . | OS . | |||
|---|---|---|---|---|---|---|---|
| HR . | P . | HR . | P . | HR . | P . | ||
| Day 7 TNFR1 ratio | ≤ 2.5 | Ref | — | Ref | — | Ref | — |
| > 2.5 | 2.44 | <.001 | 2.40 | <.001 | 1.39 | .03 | |
| Donor type | MRD | Ref | — | Ref | — | Ref | — |
| MUD | 1.87 | <.001 | 3.25 | <.001 | 1.49 | .006 | |
| Match | Yes | Ref | — | Ref | — | Ref | — |
| No | 1.93 | .01 | 1.09 | .79 | 1.25 | .28 | |
| Recipient age* | 1.05 | .35 | 1.28 | .002 | 1.10 | .03 | |
| Donor → recipient | Male → male | Ref | — | Ref | — | Ref | — |
| Female → male | 1.29 | .19 | 1.26 | .39 | 1.02 | .90 | |
| Sex | Male → female | .63 | .04 | .69 | .19 | .88 | .46 |
| Female → female | .80 | .54 | .75 | .57 | 1.01 | .98 | |
| Diagnosis and disease status | Nonmalignant | Ref | — | Ref | — | Ref | — |
| Standard risk | 1.65 | .36 | .96 | .96 | 4.26 | .05 | |
| Advanced risk | 1.74 | .31 | 1.31 | .70 | 7.67 | .005 | |
| Preparative regimen | Non-TBI | Ref | — | Ref | — | Ref | — |
| TBI | 1.14 | .63 | .61 | .20 | 1.18 | .45 | |
GVHD indicates graft-versus-host disease; TRM, treatment-related mortality; OS, overall survival; HR, hazard ratio; TNFR1; TNF receptor 1; Ref, reference group; —, not applicable; MRD, matched related donor; MUD, matched unrelated donor; Standard risk, lymphoma with chemosensitive disease, leukemia in complete remission (ie, CR1, CR2, or CR3), or untreated myelodysplastic syndrome at the time of transplantation; Advanced risk, leukemia not in remission, or lymphoma with stable or progressive disease at the time of transplantation; and TBI, total body irradiation.
For recipient age, the HR reflects the change in hazard for every 10 years.